nlp-17

2 papers2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

A gene’s or a process’s line counts the gene with the processes named after it, as NLRP3 with the NLRP3 inflammasome, and the trials of drugs aimed at it.

1 lab in 1 country

Funder: National Institutes of Health

Model organisms2

Effects

Lifespan extension

mediatesin worms2

2 studies

nlp-17 mediates lifespan extension in worms.
“including the neurotransmitters tyramine and GABA, and the neuropeptide NLP-17, in mediating longevity effects.”
Model organismsgenetic activation of the hypoxic response
The hypoxic response extends lifespan through a bioaminergic and peptidergic neural circuit
eLife26 Aug 2025Preprint
nlp-17 mediates lifespan extension in worms.
“Our findings also highlight the involvement of additional neural signaling molecules, including the neurotransmitters tyramine and GABA, and the neuropeptide NLP-17, in mediating longevity effects.”
Model organismslongevity effects of the hypoxic response
The hypoxic response extends lifespan through a bioaminergic and peptidergic neural circuit
eLife26 Aug 2025Preprint